Clinical Trials Logo

Clinical Trial Summary

This is an open-label, dose-escalation and dose-expansion phase I clinical study to evaluate the safety and tolerability of JS006 as Monotherapy and in combination with toripalimab in patients with advanced tumors who have failed standard therapies or who have no standard therapy. It is planned to enroll 69-176 patients into the study.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05061628
Study type Interventional
Source Shanghai Junshi Bioscience Co., Ltd.
Contact Bifeng Liu
Phone 18967116090
Email [email protected]
Status Recruiting
Phase Phase 1
Start date April 21, 2021
Completion date September 30, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05068856 - A Study of HRS2543 in Patients With Advanced Tumors Phase 1
Active, not recruiting NCT02419417 - Study of BMS-986158 in Subjects With Select Advanced Cancers Phase 1/Phase 2
Recruiting NCT04808453 - Phase I Study of CPI-300 in Patients With Advanced Tumors Phase 1
Recruiting NCT04198818 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Phase 1/Phase 2
Not yet recruiting NCT04151810 - Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03781362 - Study of CPI-100 in Patients With Advanced Tumors Phase 1
Recruiting NCT03908814 - Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT03444714 - Phase I Study of RiMO-301 With Radiation in Advanced Tumors Phase 1